The average cost of measles cases and adverse events following vaccinationin industrialised countries

BMC Public Health

Volumn 2, Issue , 2002, Pages 1-13

  Carabin, Hélène ^a,f   Edmunds, W John ^b   Kou, Ulla ^c   Van Den Hof, Susan ^d   Nguyen, Van Hung ^e  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b CITY UNIVERSITY   (United Kingdom)

^c WORLD HEALTH ORGANIZATION   (Switzerland)

^d NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^e Gouvernement du Quebec   (Canada)

^f UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTICONVULSIVE AGENT; ANTIPYRETIC AGENT; ANTITUSSIVE AGENT; DIAZEPAM; MEASLES VACCINE;

ADVERSE DRUG REACTION; ANAPHYLAXIS; ARTICLE; CANADA; CONTROLLED STUDY; DECISION THEORY; DISEASE SIMULATION; FEBRILE CONVULSION; FEVER; HEALTH CARE COST; HUMAN; INDUSTRIALIZATION; MEASLES; MEASLES VACCINATION; MONTE CARLO METHOD; NETHERLANDS; OTITIS MEDIA; PNEUMONIA; PREVENTIVE HEALTH SERVICE; RESPIRATORY TRACT INFECTION; SOCIAL ASPECT; SUBACUTE SCLEROSING PANENCEPHALITIS; THEORETICAL MODEL; THROMBOCYTOPENIA; UNITED KINGDOM; VIRUS ENCEPHALITIS; COST BENEFIT ANALYSIS; COST OF ILLNESS; DECISION TREE; DEVELOPED COUNTRY; ECONOMICS; MASS IMMUNIZATION; STATISTICAL MODEL; STATISTICS;

CANADA; COST OF ILLNESS; COST-BENEFIT ANALYSIS; DECISION TREES; DEVELOPED COUNTRIES; GREAT BRITAIN; HEALTH CARE COSTS; HUMANS; IMMUNIZATION PROGRAMS; MASS IMMUNIZATION; MEASLES; MEASLES VACCINE; MODELS, ECONOMETRIC; NETHERLANDS;

EID: 18744384709     PISSN: 14712458     EISSN: None     Source Type: Journal    
DOI: 10.1186/1471-2458-2-22     Document Type: Article

References (78)

1. De Serres G, Gay NJ, Farrington CP: Epidemiology of transmissible disease after elimination. Am J Epidemiol 2000, 151:1039-48
2. Cronin M, Fitzsimmons GJ: Measles outbreak in the Republic of Ireland: update. Eurosurveillance Weekly 2000, 4
3. Outbreak of measles in an army base in Germany. Eurosurveillance Weekly 2001, 5
4. Measles outbreak, Netherlands. Wkly Epidemiol Rec 2000, 75:119-21
5. Measles outbreak - Netherlands, April 1999 - January 2000. MMWR Morb Mortal Wkly Rep 2000, 49:299-303
6. Clarkson JA, Fine PE: The efficiency of measles and pertussis notification in England and Wales. Int J Epidemiol 1985, 14:153-68
7. Axnick NW, Shavell SM, Witte JJ: Benefits due to immunization against measles. Public Health Rep 1969, 84:673-80
8. Davis SF, Strebel PM, Atkinson WL, et al: Reporting efficiency during a measles outbreak in New York City, 1991. Am J Public Health 1993, 83:1011-5
9. McDonnell IF, Jorm LR: Measles epidemic in western Sydney. New South Wales Public Health Bulletin 1994, 5:59-60
10. Miller DL: Frequency of complications of measles, 1963. Report on a National inquiry by the Public Health Laboratory Service in Collaboration with the society of medical officers of health. Br Med J 1964, 2:75-8
11. Miller CL: Severity of notified measles. Br Med J 1978, 1:1253-5
12. Godoy P, Dominguez A, Alvarez J, et al: Measles epidemiology in Catalonia (Spain): implications for a regional vaccination programme. Int J Epidemiol 1999, 28:558-62
13. van den Hof S, van den Kerkhof JH, ten Ham PB, van Binnendijk RS, Conyn-van Spaendonck MA, van Steenbergen JE: [Measles epidemic in the Netherlands, 1999-2000]. Ned Tijdschr Geneesk 2001, 145:2529-33
14. Grimsrud K: Cases of measles in the Alberta's (Canada) outbreak. Personal Communication 2001
15. Godoy P, Dominguez A, Camps N, et al: [Validity of the notifications of red measles based on clinical diagnosis in Cataluna, Spain]. Enfermedades Infecciosas y Microbiologia Clinica 1999, 17:180-3
16. Dales LG, Kizer KW, Rutherford GW, Pertowski CA, Waterman SH, Woodford G: Measles epidemic from failure to immunize. West J Med 1993, 159:455-64
17. Hanratty B, Holt T, Duffell E, et al: UK measles outbreak in non-immune anthroposophic communities: the implications for the elimination of measles from Europe. Epidemiol Infect 2000, 125:377-83
18. Mason WH, Ross LA, Lanson J, Wright HT Jr: Epidemic measles in the postvaccine era: evaluation of epidemiology, clinical presentation and complications during an urban outbreak. Pediatr Infect Dis J 1993, 12:42-8
19. Loras-Duclaux I, David L, Peyramond D, Floret D, Lachaux A, Hermier M: [Epidemiological study and cost evaluation of measles in Lyons hospitals over a 5-year period]. Pédiatrie 1988, 43:451-4
20. Shiell A, Jorm LR, Carruthers R, Fitzsimmons GJ: Cost-effectiveness of measles outbreak intervention strategies. Aust N Z J Public Health 1998, 22:126-32
21. Farrington CP: Subacute sclerosing panencephalitis in England and Wales: transient effects and risk estimates. Stat Med 1991, 10:1733-44
22. Madge N, Diamond J, Miller D, et al: The National Childhood Encephalopathy study: a 10-year follow-up. A report on the medical, social, behavioural and educational outcomes after serious, acute, neurological illness in early childhood. Dev Med Child Neurol 1993, 35:1-118
23. Hart YM, Shorvon SD: The nature of epilepsy in the general population. I. Characteristics of patients receiving medication fro epilepsy. Epilepsy Res 1995, 21:43-9
24. Carabin H, Gyorkos TW, Soto JC, Penrod J, Joseph L, Collet J-P: Estimation of direct and indirect costs due to common infections in toddlers attending daycare centres. Pediatrics 1999, 103:556-64
25. Hastings A, Hostler A, Solen A: Measles: who pays the cost? Br Med J (Clin Res Ed) 1987, 294:1527-8
26. Brisson M, Edmunds WJ: The cost-effectiveness of varicella vaccination in Canada. Vaccine 2002, 20:1113-25
27. Duclos P, Ward BJ: Measles vaccines: a review of adverse events. Drug Saf 1998, 19:435-54
28. National Advisory Committee on Immunization: Canadian Immunization guide. Ottawa, Canadian Medical Association 1998
29. National Health and Medical Research Council: The Australian Immunisation Handbook. Canberra, AGPS 2000
30. Taylor B, Miller E, Farrington CP, et al: Autism and measles, mumps, and rubella vaccine: no epidemiological evidence for a causal association. Lancet 1999, 353:2026-9
31. Kaye JA, del Mar Melero-Montes M, Jick H: Mumps, measles and rubella vaccine and the incidence of autism recorded by general practitioners: a time trend analysis. BMJ 2001, 322:460-3
32. Strauss B, Bigham M: Does measles-mumps-rubella (MMR) vaccination cause inflammatory bowel disease and autism? Can Commun Dis Rep 2001, 27:65-72
33. Miller D, Wadsworth J, Diamond J, Ross D: Measles vaccination and neurological events. Lancet 1997, 349:730-1
34. Barlow WE, Davis RL, Glasser JW, et al: The risk of seizures after receipt of whole-cell pertussis or measles, mumps, and rubella vaccine. N Engl J Med 2001, 345:656-61
35. Virtanen M, Peltola H, Paunio M, Heinonen OP: Day-to-day reactogenecity and the healthy vaccinee effect of Measles-Mumps-Rubella Vaccination. Pediatrics 2000, 106:e62-e68
36. Davis RL, Marcuse E., Black S, et al: MMR2 immunization at 4 to 5 years and 10 to 12 years of age: a comparison of adverse clinical events after immunization in the Vaccine Safety Datalink project. The Vaccine Safety Datalink Team. Pediatrics 1997, 100:767-71
37. Lieu T, Black SB, Ray GT, Martin KE, Shinefield HR, Weniger BG: The hidden costs of infant vaccination. Vaccine 2000, 19:33-41
38. Netten A, Curtis L: Unit costs for health and social care 2000. Canterbury, Personal Social Services Research Unit 2000
39. Institute of Health Economics: A national list of provincial costs for health costs: 1997/8. Edmonton, Institute of Health Economics 2000
40. Statistics Netherlands: Income, wage, labour costs and working hours of employees. Amsterdam, Statistics Netherlands 2001 [http://www.cbs.nl/en/figures/ keyfigures/sip_400z.htm]
41. National Statistics: New Earning Survey 2000. Average weekly Earnings. London: National Statistics. The official UK statistics site 2001 [http://www.statistics.gov.uk/statbase/xsdataset.asp]
42. Statistics Canada: Ottawa: Statistics Canada 2001 [http://www.stat-can. ca/english/Pgdb/People/Labour/labor01a.htm]
43. Organisation for Economic Co-Operation and Development (OECD): Health Data 1998. Paris: Organisation for Economic Co-Operation and Development (OECD) 1998
44. IMS Canada: Retail pharmacy dispensed prescription costs: Canada and provinces. Montreal: IMS Canada 1999
45. British National Formulary: London: British National Formulary 2001 [http://bnf.vhn.net/home]
46. Boots the Chemist: Price of OTC drugs in the UK. Boots 2001 [http://bnf.vhn.net/home]
47. Heany DC, Sander JWAS, Shorvon SD: Comparing the cost of epilepsy across eight European countries. Epilepsy Res 2001, 43:89-95
48. Historical Currency Exchange Rates. OANDA 2001 [http://www.oanda.com/ convert/fxhistory]
49. Sanchez MA, Blower SM: Uncertainty and sensitivity analysis of the basic reproductive rate. Am J Epidemiol 1997, 145:1127-37
50. @Risk: Risk Analysis and simulation add-in for Excel (version 4). New York (NY), Palisade Corporation 2000
51. Taracena DP, Monton JL, Cristobal P, Gonzalez F, Casas J: [The cost of measles in Spain]. An Esp Pediatr 1983, 19:383-8
52. Beutels P, van Damme P, van Casteren V, Gay NJ, De Schrijver K, Meheus A: The difficult quest for data on "vanishing" vaccine-preventable infections in Europe: the case of measles in Flanders (Belgium). Vaccine 2002
53. White CC, Koplan JP, Orenstein WA: Benefits, risks and costs of immunization for measles, mumps and rubella. Am J Public Health 1985, 75:739-44
54. Pelletier L, Chung P, Duclos P, Manga P, Scott J: A benefit-cost analysis of two-dose measles immunization in Canada. Vaccine 1998, 16:989-96
55. Miller MA, Redd S, Hadler S, Hinman A: A model to estimate the potential economic benefits of measles eradication for the United States. Vaccine 1998, 16:1917-22
56. Ekblom M, Elo O, Laurinkari J, Niemela P: Costs and benefits of measles vaccination in Finland. Scand J Soc Med 1978, 6:111-5
57. Wiedermann G, Ambrosch F: Cost-benefit calculations of vaccinations against measles and mumps in Austria. Dev Biol Stand 1979, 43:273-7
58. Bloch AB, Orenstein WA, Stetler HC, et al: Health impact of measles vaccination in the United States. Pediatrics 1985, 76:524-32
59. Carrasco JL, Lardinois R: Formula for calculating vaccine profitability. Vaccine 1987, 5:123-7
60. Moiraghi Ruggeni A, Zotti Z, Pedronetto A, Milano R, Garella D, Sachetti C: I ricoveri ispedalieri in Torino per morbillo e relative complicanze nel periodo 1973-1983: valuazioni sanitarie ed economiche, in raporto alla opportunita dell'intervento vaccinale. Bol Ist Sieroterio Milano 1986, 65:502-11
61. Hatziandreu E, Halpern NT, Brown RE, Watson GA: Cost-benefit analysis of the measles-mumps-rubella (MMR) vaccine. Arlington, VA: Center for Disease Control and Prevention 1994
62. Center for Disease Control and Prevention: Public attitudes towards immunization. Atlanta: Center for Disease Control and Prevention 1977
63. Miller C, Farrington CP, Harbert K: The epidemiology of subacute sclerosing panencephalitis in England and Wales 1970-1989. Int J Epidemiol 1992, 21:998-1006
64. van den Hof S: Costs of measles in the Netherlands. Personal communications 2001
65. Cope ANK, Frank PF, Montgomery J, et al: Measles-Duval County, Florida, 1991-1992. Morb Mortal Wkly Rep 1993, 42:81-3
66. Mansoor O: Vaccine adverse events reported in New Zealand 1990-5. N Z Med J 1997, 10:270-2
67. Chavez G, Ellis A: Pediatric hospital admissions for measles. Lessons from the 1990 epidemic. West J Med 1996, 165:20-25
68. Bentsi-Enchill A, Hardy M, Koch J, Duclos P: Adverse events temporally associated with vaccines - 1992 report. Can Commun Dis Rep 1995, 21:117-128
69. D'Souza RM, Campbell-Lloyd S, Isaacs D, et al: Adverse events following immunisation associated with the 1998 Australian measles control campaign. Commun Dis Intell 2000, 24:27-33
70. Department of Health: Measles Rubella (MR) Immunisation Campaign in England 1994. One Year On. London: Department of Health 1995
71. Patja A, Davidkin I, Kurki T, Kallio MJ, Valle M, Peltola H: Serious adverse events after measles-mumps-rubella vaccination during a fourteen-year prospective follow-up. Pediatr Infect Dis J 2000, 19:1127-34
72. Chen RT, Moses JM, Markowitz LE, Orenstein WA: Adverse events following measles-mumps-rubella and measles vaccinations in college students. Vaccine 1991, 9:297-9
73. Roberts RJ, Sandifer QD, Evans MR, Nolan-Farrell MZ, Davis PM: Reasons for non-uptake of measles, mumps, and rubella catch up immunisation in a measles epidemic and side effects of the vaccine. BMJ 1995, 310:1629-32
74. Rosenthal S, Chen R: The reporting sensitivities of two passive surveillance systems for vaccine adverse events. Am J Public Health 1995, 85:1706-9
75. Griffin MR, Ray WA, Mortimer EA, Fenichel GM, Schaffner W: Risk of seizures after measles-mumps-rubella immunization. Pediatrics 1991, 88:881-5
76. Okuno Y, Nakao T, Ishida N, et al: Incidence of subacute sclerosing panencephalitis following measles and measles vaccination in Japan. Int J Epidemiol 1989, 18:684-9
77. Jonville-Bera AP, Autret E, Galy-Eyraud C, Hessel L: Thrombocytopenic purpura after measles, mumps and rubella vaccination: a retrospective survey by the French regional pharmacovigilance centres and pasteur-merieux serums and vaccines. Pediatr Infect Dis J 1996, 15:44-8
78. Miller E, Waight P, Farrington CP: Idiopathic thrombocytopenic purpura and MMR vaccine. Arch Dis Child 2001, 84:227-9